Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231568 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01231568 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants.
The verdict
NCT01231568, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study is designed to evaluate the effects of a high fat meal on the pharmacokinetics of 150 mg of GSK2118436, as well as the effects of particle size on the relative bioavailability of GSK2118436.
Interventions
- DRUG Regimen A
- DRUG Regimen B
- DRUG Regimen C
- DRUG Regimen D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-10-21 |
| Est. Completion | 2011-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01231568
The ClinicalTrials.gov registry entry for NCT01231568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Regimen A is the first listed.
NCT01231568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01231568 about?
NCT01231568 is a clinical study titled "An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor". The study is designed to evaluate the effects of a high fat meal on the pharmacokinetics of 150 mg of GSK2118436, as well as the effects of particle size on the relative bioavailability of GSK2118436.
What is the current status of trial NCT01231568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-10-21. Estimated completion is 2011-05-13.
What interventions are being tested in trial NCT01231568?
The interventions under investigation include: Regimen A (DRUG), Regimen B (DRUG), Regimen C (DRUG), Regimen D (DRUG).
Who is sponsoring clinical trial NCT01231568?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.